



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



29 November 2012

By Facsimile: 1300 300 021

Manager Companies
Company Announcements Office
Australian Securities Exchange Limited
Level 4, Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Sir

**Results of 2012 Annual General Meeting
Bioxyne Limited**

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary

Yours faithfully

A handwritten signature in black ink, appearing to read "Raymer".

Laura Raymer

Company Secretary



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



**Australian Securities Exchange Limited
Companies Announcements Office
SYDNEY**

29 November 2012

ANNUAL GENERAL MEETING

Bioxyne Limited (ASX: BXN) advises the results of voting at today's Annual General Meeting.

As a result of the decision of members at today's meeting, Dr William Harrison will leave the Board. Mr Ian Mutton also advised his resignation from the Board. Mr Tony Ho was appointed to the position of Chairman by the Board.

Bioxyne acknowledges the contribution of the retiring Directors.

Results of poll and resolutions

The Results of the poll on each resolution are provided in the attached letter from the polling officer.

For Further information please contact:

David Radford
Chief Executive Officer
Tel: +61 (0) 407-218-922

Tim Allerton or Andrew Geddes
CityPR
(02) 9267 4511



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company's lead therapy, HI-164OV is based on the Company's proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common

diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit www.bioxyne.com

COPD

Chronic Obstructive Pulmonary Disease (COPD) is a disease largely caused by smoking but with a rising number of new cases caused by pollution in developing countries like China and India. The global demand for COPD treatments is growing rapidly with an analysis by the Australian Lung Foundation in 2008 indicating the wide economic cost of to the Australian economy in 2010 was estimated to be \$9 billion in direct and indirect costs, with \$1 billion incurred in direct health system expenditure. There are currently no effective treatments for COPD and 25 per cent of COPD patients admitted to hospital die within one year. Reducing hospital admissions is crucial and preventing exacerbations is the main choice of therapy. More than 15 per cent of new patients have never smoked and

Industrial pollution is viewed as a major risk factor in the onset of COPD. It is estimated COPD will be third leading cause of mortality in the next decade, behind heart failure and cancer.

29 November 2012

The Chairman
Bioxyne Limited
Suite 1A, Level 2
802 Pacific Highway,
Gordon, NSW 2072

Poll Report

I, the Returning Officer appointed by you in connection with the voting by poll on the motion set out below at the Annual General Meeting of the Members of Bioxyne Limited held at The Institute of Chartered Accountants, The Phillip Room, Level 1, 33 Erskine Street, Sydney NSW 2000 on 29 November 2012 at 2:30 PM, report as follows:

1) Adoption of Remuneration Report

	Number	%
Votes cast 'FOR' the motion	24,245,147	37.09
Votes cast 'AGAINST' the motion	41,124,460	62.91
TOTAL VOTES CAST	65,369,607	100.00
Votes "Abstained"	45,497	

The resolution was not carried as an ordinary resolution.

2) Re-election of William Harrison as Director

	Number	%
Votes cast 'FOR' the motion	30,001,680	45.56
Votes cast 'AGAINST' the motion	35,854,164	54.44
TOTAL VOTES CAST	65,855,844	100.00
Votes "Abstained"	1,301,422	

The resolution was not carried as an ordinary resolution.

5) Approval of 10% Placement Facility

	Number	%
Votes cast 'FOR' the motion	29,483,872	43.90
Votes cast 'AGAINST' the motion	37,670,894	56.10
TOTAL VOTES CAST	67,154,766	100.00
Votes "Abstained"	2,500	

The resolution was not carried as a special resolution.

Yours faithfully

Maria Dzopalic
Returning Officer
Computershare Investor Services Pty Limited

1) Adoption of Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
7,792,920	50,877,607	45,497	193,259

The motion was not carried as an ordinary resolution on a poll the details of which are:

For	Against	Abstain
24,245,147	41,124,460	45,497

2) Re-election of William Harrison as Director

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
25,636,150	32,154,419	1,301,422	538,451

The motion was not carried as an ordinary resolution on a poll the details of which are:

For	Against	Abstain
30,001,680	35,854,164	1,301,422

3) Re-election of Patrick Ford as Director

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
57,703,548	87,021	1,301,422	538,451

The motion was carried as an ordinary resolution on a show of hands.

4) Issue of Shares

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
8,560,991	50,499,225	31,775	538,451

The motion was withdrawn from the meeting.

5) Approval of 10% Placement Facility

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
25,251,076	33,838,415	2,500	538,451

The motion was not carried as a special resolution on a poll the details of which are:

For	Against	Abstain
29,483,872	37,670,894	2,500